R&D News
-
-
- 2020-09-21
Brief Product News | New Progress in Henlius Anti-HER2 Therapy! First Patient Dosed in Phase 1 Clinical Trial of Henlius Pertuzumab Biosesesimilar HLX11
HLX11 was independently developed by Henlius with the pertuzumab originator as reference drug and the development is in accordance with China's biosesesimilar guidelines.
-
-
-
- 2020-09-10
Henlius Bevacizumab Biosesesimilar HLX04 Receives NDA Acceptance Notification from NMPA
HLX04 was developed with the bevacizumab originator as reference product and the development process is in line with China’s biosesesimilar guidelines.
-